Phathom Pharmaceuticals Inc
$ 11.46
-8.76%
02 Mar - close price
- Market Cap 979,849,000 USD
- Current Price $ 11.46
- High / Low $ 12.33 / 11.44
- Stock P/E N/A
- Book Value -6.13
- EPS -3.76
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -34.89 %
- 52 Week High 18.31
- 52 Week Low 2.21
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Analyst Target Price
$23.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-07 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-10 | 2023-02-28 |
| Reported EPS | -0.15 | -0.79 | -1.07 | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 | -0.76 | -0.84 | -0.89 | -1.33 |
| Estimated EPS | -0.47 | -0.91 | -1.066 | -1.08 | -1.49 | -1.38 | -1.31 | -1.08 | -0.89 | -0.98 | -1.26 | -1.35 |
| Surprise | 0.32 | 0.12 | -0.004 | 0.03 | 0.17 | -0.18 | -0.11 | -0.31 | 0.13 | 0.14 | 0.37 | 0.02 |
| Surprise Percentage | 68.0851% | 13.1868% | -0.3752% | 2.7778% | 11.4094% | -13.0435% | -8.3969% | -28.7037% | 14.6067% | 14.2857% | 29.3651% | 1.4815% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.42 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAT
2026-03-02 22:52:33
Phathom Pharmaceuticals (NASDAQ:PHAT) saw its stock price drop by 6.5% on Monday, trading at $11.74 with higher-than-average volume. Despite this, MarketBeat shows a "Moderate Buy" consensus rating with an average analyst price target of $22.25. The clinical-stage biopharmaceutical company, focused on GI diseases, modestly beat quarterly EPS estimates and institutional investors hold approximately 99% of its shares.
2026-03-01 09:51:59
Guggenheim has increased its price target for Phathom Pharmaceuticals (PHAT) from $20 to $25, maintaining a Buy rating. This upgrade follows Phathom's strong fiscal Q4 and full-year 2025 results, which showed a significant 217% increase in FY25 net revenues and progress towards profitability in early Q3 2026. The company also strengthened its financial position through an equity offering and debt modification.
2026-02-28 02:52:48
This article provides a detailed financial overview of Phathom Pharmaceuticals, Inc. (PHAT), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2025. It highlights the company's significant revenue growth of 216.9% year-over-year but also notes its unprofitability with a net income of -$221.2M and low earnings quality. The analysis points to weak financial health, a negative operating margin, and concerns about debt-servicing ability.
2026-02-27 21:52:06
Phathom Pharmaceuticals (NASDAQ:PHAT) surpassed Q4 earnings estimates by $0.01 per share, reporting a loss of $0.08 EPS against a consensus of ($0.09). The company also delivered strong Q4 revenue of $57.58 million and guided 2026 revenue between $320M–$345M, expecting to achieve operating profitability by Q3 2026 and cash-flow positivity in 2027. Despite an equity offering that introduced dilution risk, the company improved its capital structure and strengthened its commercial momentum in the GI market.
2026-02-27 12:52:06
H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Phathom Pharmaceuticals (PHAT) with a $26.00 price target. This positive outlook is driven by the early commercial success of VOQUEZNA, the significant unmet need in the GERD market, and Phathom's strengthened financial position through recent equity financing and debt renegotiations. The company's focused strategy and consistent prescription growth, coupled with a clear path to operating profitability by Q3 2026, further support the analyst's optimistic stance.
2026-02-27 08:22:06
Phathom Pharmaceuticals, Inc. reported strong Q4 and full-year 2025 results, exceeding revenue and expense guidance, driven by the success of VOQUEZNA. The company has enhanced its capital structure by modifying its term loan agreement, extending maturity, and reducing interest expenses, which is expected to ensure sufficient cash to meet all obligations. Phathom forecasts continued growth and anticipates achieving operational profitability by Q3 2026 and cash flow positivity in 2027, focusing on a GI-centric sales strategy and potential future asset acquisitions.
